Par Pharm Company Profile
✉ Email this page to a colleague
What is the competitive landscape for PAR PHARM, and what generic alternatives to PAR PHARM drugs are available?
PAR PHARM has one hundred and fifty-three approved drugs.
There is one US patent protecting PAR PHARM drugs. There are thirteen tentative approvals on PAR PHARM drugs.
There are nine patent family members on PAR PHARM drugs in eight countries and one hundred and ninety supplementary protection certificates in fifteen countries.
Summary for Par Pharm
| International Patents: | 9 |
| US Patents: | 1 |
| Tradenames: | 98 |
| Ingredients: | 96 |
| NDAs: | 153 |
| Patent Litigation for Par Pharm: | See patent lawsuits for Par Pharm |
| PTAB Cases with Par Pharm as petitioner: | See PTAB cases with Par Pharm as petitioner |
Drugs and US Patents for Par Pharm
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Par Pharm | RISPERIDONE | risperidone | TABLET, ORALLY DISINTEGRATING;ORAL | 077494-005 | Apr 30, 2009 | AB | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Par Pharm | OLANZAPINE AND FLUOXETINE HYDROCHLORIDE | fluoxetine hydrochloride; olanzapine | CAPSULE;ORAL | 077742-005 | Nov 2, 2012 | AB | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Par Pharm | THIORIDAZINE HYDROCHLORIDE | thioridazine hydrochloride | TABLET;ORAL | 088322-001 | Dec 5, 1983 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Par Pharm
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Par Pharm | NASCOBAL | cyanocobalamin | GEL, METERED;NASAL | 019722-001 | Nov 5, 1996 | 4,724,231 | ⤷ Try a Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for PAR PHARM drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Nasal Spray | 500 mcg/spray | ➤ Subscribe | 2017-04-28 |
International Patents for Par Pharm Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Mexico | 2007013118 | ⤷ Try a Trial |
| Canada | 2605413 | ⤷ Try a Trial |
| European Patent Office | 1948613 | ⤷ Try a Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Par Pharm Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2330892 | CA 2016 00062 | Denmark | ⤷ Try a Trial | PRODUCT NAME: GLYCEROLPHENYLBUTYRAT; REG. NO/DATE: EU/1/15/1062/001-004 20151201 |
| 0806968 | SPC/GB07/011 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: GADOFOSVESET TRISODIUM; REGISTERED: UK EU/1/05/313/001 20051003; UK EU/1/05/313/002 20051003; UK EU/1/05/313/003 20051003; UK EU/1/05/313/004 20051003; UK EU/1/05/313/005 20051003; UK EU/1/05/313/006 20051003; UK EU/1/05/313/007 20051003; UK EU/1/05/313/008 20051003; UK EU/1/05/313/009 20051003 |
| 2563920 | CR 2019 00001 | Denmark | ⤷ Try a Trial | PRODUCT NAME: INOTERSEN AND SALT THEREOF, INCLUDING SODIUM SALTS; REG. NO/DATE: EU/1/18/1296 20180710 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
